Nexalin Technology reports 77.8% anxiety response rate in Brazil trial

June 10, 2026 9:15 AM

Nexalin Technology Inc. (NASDAQ: NXL) completed an 8-week clinical trial in Brazil demonstrating a 77.8% anxiety response rate using its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found